As per MRFR analysis, the Plaque Psoriasis Market Size was estimated at 6.75 (USD Billion) in 2023.The Plaque Psoriasis Market Industry is expected to grow from 6.98(USD Billion) in 2024 to 10.1 (USD Billion) by 2035. The Plaque Psoriasis Market CAGR (growth rate) is expected to be around 3.42% during the forecast period (2025 - 2035)
The Global Plaque Psoriasis Market is currently experiencing numerous noteworthy trends that are being driven by the rising prevalence of psoriasis and the increasing awareness of patients and healthcare providers. An increase in the number of cases worldwide has been attributed to the rise in lifestyle-related risk factors, including stress and obesity. In addition, the implementation of sophisticated treatment options, such as biologics and targeted therapies, has revolutionized the management of plaque psoriasis, resulting in improved patient outcomes and increased adherence to treatment regimens.
Additionally, the market is experiencing a transition to personalized medicine, in which therapies are customized to the unique requirements of each patient by utilizing genetic and biomarker data. The expansion of access to innovative therapies in underserved regions presents opportunities for growth. The increasing emphasis on healthcare infrastructure in developing countries may increase the diagnosis and treatment of psoriasis. The growing trend of telemedicine, which enables patients to consult with dermatologists remotely, has created a high demand for convenient and effective home care options.
This is an additional area that is suitable for exploration. In recent years, there has been a significant shift toward integrated care models that incorporate dermatology with other specialties to offer comprehensive treatment approaches. Patient-centric initiatives are gathering momentum, with an emphasis on improving the quality of life and providing psychological support to individuals with plaque psoriasis.
Additionally, the popularity of digital health solutions, such as wearables and mobile applications, is on the rise, enabling patients to monitor their condition and treatment responses. These trends will significantly influence the future of the Global Plaque Psoriasis Market as they continue to develop.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Global Plaque Psoriasis Market Industry is driven by the increasing prevalence of plaque psoriasis, which affects millions of individuals globally. According to the Global Health Organization, approximately 2-3% of the global population suffers from this chronic skin condition, which translates to roughly 160 million people worldwide. This staggering statistic underscores the demand for effective treatment options across various demographics. Moreover, established organizations such as the National Psoriasis Foundation have emphasized the need for innovative therapies that cater to this large patient base.
As the population ages, the incidence of plaque psoriasis is expected to grow, leading to a higher demand for pharmaceutical interventions and related healthcare services, thus propelling market growth in the Global Plaque Psoriasis Market Industry.
Technological advancements in treatment options for plaque psoriasis are significantly boosting the Global Plaque Psoriasis Market Industry. The introduction of biologics and targeted therapies has revolutionized the way plaque psoriasis is treated. According to recent studies published by the American Academy of Dermatology, biologic treatments have shown a 75% improvement in skin clearance among patients, significantly impacting treatment outcomes.
Leading pharmaceutical companies such as AbbVie and Amgen are investing heavily in the Research and Development (R&D) of new biologic drugs, which promise enhanced efficacy and fewer side effects. These advancements are expected to meet the growing demand for effective treatments, further fueling market growth.
The rise in awareness about plaque psoriasis and ongoing education and support programs are playing a critical role in driving the Global Plaque Psoriasis Market Industry. Organizations like the National Psoriasis Foundation and various global dermatology associations are actively engaging in campaigns to educate the public about the condition. Increased awareness has led to early diagnosis and treatment, which is essential for managing the disease effectively.
According to public health data, early intervention can reduce the severity of symptoms by 40%, improving patient quality of life. The focus on education not only empowers patients but also stimulates demand for healthcare services and treatment solutions.
The Global Plaque Psoriasis Market, segmented by Treatment Type, reveals an evolving landscape in the management of this chronic skin condition, with a projected valuation of 6.98 USD Billion in 2024 and anticipated growth to 10.1 USD Billion by 2035. This market encompasses various treatment options, including Topical Treatments, Systemic Treatments, Phototherapy, and Biologic Therapies, reflecting a comprehensive approach to addressing plaque psoriasis. Among these, Topical Treatments are significant, valued at 1.88 USD Billion in 2024 and expected to rise to 2.85 USD Billion by 2035, highlighting their ongoing role as the first line of therapy due to their accessibility and ease of use.
Systemic Treatments also play a critical role, commanding a valuation of 2.09 USD Billion in 2024 and projected to increase to 3.06 USD Billion by 2035. This segment is particularly important for patients with moderate to severe forms of psoriasis, as they address more widespread conditions effectively. Phototherapy, though a smaller segment, is experiencing notable growth, increasing from a valuation of 1.02 USD Billion in 2024 to 1.49 USD Billion by 2035, reflecting its significance in treatment plans where traditional methods may not suffice.
Biologic Therapies dominate this market segment with a considerable valuation of 2.99 USD Billion in 2024, expected to rise to 4.7 USD Billion by 2035. Their advanced mechanism of action targeting specific pathways in the immune system represents a transformative approach to managing plaque psoriasis, thus explaining their prevalence among treatment choices. Each treatment type reflects a particular approach to tackling the challenges of plaque psoriasis, driven by ongoing research, clinical advancements, and the increasing prevalence of this dermatological condition across the globe.
The market growth in the Global Plaque Psoriasis Market" data aligns with wider healthcare trends emphasizing personalized medicine, leading to more tailored treatment options that cater to individual patient needs and preferences. As awareness of plaque psoriasis spreads and the demand for effective treatments increases, the various categories within the market will continue to evolve, underlined by supportive policies from healthcare authorities and an expanding base of healthcare practitioners specializing in dermatology. This supportive framework aids in driving market statistics further, offering opportunities to innovate and enhance holistic care standards in managing plaque psoriasis in the global arena, ensuring a comprehensive response to this chronic condition.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Global Plaque Psoriasis Market remains diverse, with the Route of Administration segment playing a crucial role in shaping treatment strategies. As of 2024, the overall market value is expected to be 6.98 USD Billion, reflecting the increasing demand for effective therapeutic options. Within this segment, treatment methods can be categorized into topical, oral, injectable, and intravenous approaches. Topical treatments are significant due to their localized effect and ease of use, while oral medications offer systemic treatment options for patients seeking convenience.
Injectable therapies have gained prominence, particularly due to advancements in biologics that target specific immune pathways, addressing the underlying causes of psoriasis. Intravenous administration is reserved for more severe cases, providing immediate therapeutic effects. The Global Plaque Psoriasis Market data indicates a steady growth trend, driven by rising prevalence rates, expanded research and development efforts, and improved healthcare access.
However, challenges such as high costs of treatment and reimbursement hurdles may impact market penetration. Nonetheless, ongoing innovations in drug delivery methods and an increasing focus on personalized medicine present substantial opportunities for growth in the Global Plaque Psoriasis Market industry. The market statistics suggest that these developments will further enhance treatment outcomes and patient satisfaction, ensuring a robust market landscape moving forward.
The Global Plaque Psoriasis Market is significantly influenced by Disease Severity, which includes classifications such as Mild, Moderate, and Severe cases. As of 2024, the overall market was valued at approximately 6.98 Billion USD and is projected to grow to 10.1 Billion USD by 2035, reflecting a steady demand for effective treatment options across varying levels of severity. The market segmentation emphasizes the diverse needs associated with each severity type. Mild cases are often characterized by less extensive skin involvement, while Moderate and Severe cases present more extensive lesions that can greatly impact the quality of life.
These distinctions are crucial as they drive the development and innovation of targeted therapies, allowing for a more personalized approach to treatment. Additionally, Increased awareness regarding plaque psoriasis and growing research initiatives are contributing to market growth. Furthermore, challenges such as high treatment costs and the need for insurance coverage remain significant. However, the potential for new biologics and therapies targeting specific severity levels presents numerous opportunities for stakeholders. Overall, the Global Plaque Psoriasis Market data reflects a robust landscape evolving to meet the complexities of disease severity in patients worldwide.
The Global Plaque Psoriasis Market is projected to reach a value of 6.98 USD Billion by 2024, influenced significantly by the demographics of patients affected by this skin condition. The market showcases a diverse segmentation among patients, primarily classified into Adults, Children, and the Elderly. The Adult demographic typically accounts for a substantial portion of the patient population, as Plaque Psoriasis commonly develops in adulthood, profoundly impacting quality of life and work productivity.
The rising prevalence of this condition within older age groups highlights the growing need for targeted treatments and healthcare solutions. Children, while representing a smaller percentage of the overall demographic, require specialized care due to the unique challenges of managing chronic skin conditions at a young age, necessitating a focus on gentle treatment options. The Elderly segment also holds significant importance due to the increased likelihood of comorbidities that can complicate treatment strategies. Overall, understanding these demographics is essential for effectively addressing the needs of the Global Plaque Psoriasis Market and developing appropriate therapies and support systems tailored to each group.
The Global Plaque Psoriasis Market exhibits substantial regional diversity in its revenue contributions, with North America leading the pack, generating a valuation of 3.1 USD Billion in 2024 and expected to grow to 4.4 USD Billion by 2035. This region's dominance can be attributed to high healthcare expenditures and advanced treatment options available. Europe follows as a significant contributor with a market value of 2.1 USD Billion in 2024, projected to reach 3.1 USD Billion in 2035, fueled by increasing awareness and access to innovative therapies.
The APAC region, valued at 1.2 USD Billion in 2024 with a forecasted growth to 1.8 USD Billion in 2035, is gaining attention due to rising incidences of psoriasis alongside improving healthcare infrastructure. South America holds a smaller share, expected to grow from 0.4 USD Billion in 2024 to 0.6 USD Billion in 2035, reflecting the region's developing healthcare frameworks. Meanwhile, the MEA region, starting at 0.08 USD Billion in 2024, is projected to reach 0.2 USD Billion by 2035, showcasing potential growth opportunities as awareness and treatment access improve.
This regional segmentation of the Global Plaque Psoriasis Market highlights the varied challenges and growth drivers influencing market dynamics across different geographical areas.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The competitive landscape of the Global Plaque Psoriasis Market illustrates a dynamic interplay among leading pharmaceutical companies as they strive to develop innovative treatment solutions for this chronic skin condition. As awareness about skin disorders grows and research advances, the market has witnessed a proliferation of biologics, systemic medications, and topical therapies aimed at managing plaque psoriasis. With increasing investments in research and development, companies are vying for a greater market share by improving existing therapies and creating novel medications that cater to a diverse patient demographic. The competition is fueled not only by product innovation but also by strategic partnerships, mergers, and collaborations aimed at enhancing market outreach and efficacy.
Pfizer stands out in the Global Plaque Psoriasis Market with a robust portfolio that emphasizes its commitment to patient care through effective treatment regimens. The company focuses on delivering advanced pharmaceuticals and has established itself as a key player by continuously investing in research to augment its offerings for psoriasis management. Pfizer's strengths lie in its strong global presence, extensive distribution channels, and significant resources for conducting clinical trials that address unmet patient needs. Leveraging its advanced research capabilities and a reputation for high-quality medicines, Pfizer engages in strategic alliances, which bolster its standing in the market and enable the development of cutting-edge psoriasis therapies that align with patient preferences and health system demands.
AbbVie has carved a significant niche in the Global Plaque Psoriasis Market through its innovative product lineup, helping shape treatment paradigms for patients worldwide. Known for its flagship therapies, AbbVie continuously expands its portfolio to provide differentiated solutions that improve patients' quality of life. The company's strong market presence is underpinned by its commitment to research, which allows it to introduce unique mechanisms of action in its therapeutic offerings. AbbVie's robust pipeline reflects its focus on addressing various aspects of plaque psoriasis while also responding proactively to competition through strategic mergers and acquisitions that enhance its capabilities and resources. The company's ability to adapt to evolving market trends, combined with its dedication to improving patient outcomes, positions AbbVie as a formidable competitor in the global landscape of psoriasis treatment.
The Global Plaque Psoriasis Market has witnessed significant developments recently, with Pfizer and AbbVie continuing to dominate with their leading therapies. Recent data indicates that the market is expected to grow substantially over the next few years, driven by increasing awareness and improved diagnostic techniques. In November 2022, Gilead Sciences announced the launch of a novel drug targeting moderate to severe plaque psoriasis, enhancing its market position. Companies like Eli Lilly and Johnson and Johnson are also making strides with their pipeline products, demonstrating advancements in treatment options.
Meanwhile, Novartis experienced a notable increase in market valuation following positive clinical trial results for its latest psoriasis therapy in March 2023. The merger landscape has seen activity, including Regeneron Pharmaceuticals acquiring a smaller biotech firm in July 2023 to expand its psoriasis treatment offerings. Market dynamics are further influenced by collaborations among major players like Amgen and Sanofi, focusing on Research and Development to innovate and provide better therapeutic options. The ongoing research initiatives and a surge in the patient population seeking effective treatments underscore the competitive environment and the market’s potential for growth and evolution.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 6.75(USD Billion) |
| MARKET SIZE 2024 | 6.98(USD Billion) |
| MARKET SIZE 2035 | 10.1(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.42% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Pfizer, AbbVie, Gilead Sciences, Eli Lilly, Johnson and Johnson, UCB, Incyte, Novartis, Celgene, Regeneron Pharmaceuticals, BristolMyers Squibb, Merck, AstraZeneca, Amgen, Sanofi |
| SEGMENTS COVERED | Treatment Type, Route of Administration, Disease Severity, Patient Demographics, Regional |
| KEY MARKET OPPORTUNITIES | Biologic therapies growth, Increased prevalence rates, Demand for personalized medicine, Expanding telehealth services, Innovative treatment delivery methods |
| KEY MARKET DYNAMICS | Increasing prevalence of psoriasis, Rising demand for biologic therapies, Growing awareness of disease, Advancements in treatment options, Strong pipeline of new drugs |
| COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Global Plaque Psoriasis Market is expected to be valued at 6.98 USD Billion in 2024.
By 2035, the Global Plaque Psoriasis Market is projected to reach 10.1 USD Billion.
The expected CAGR for the Global Plaque Psoriasis Market from 2025 to 2035 is 3.42%.
North America is expected to hold the largest market share, valued at 3.1 USD Billion in 2024.
The Biologic Therapies segment is expected to grow from 2.99 USD Billion in 2024 to 4.7 USD Billion by 2035.
Key competitors in the market include Pfizer, AbbVie, Gilead Sciences, and Eli Lilly among others.
The Systemic Treatments segment is estimated to have a market size of 2.09 USD Billion in 2024.
The APAC region is anticipated to grow to a market size of 1.8 USD Billion by 2035.
The Topical Treatments segment is projected to be worth 2.85 USD Billion in 2035.
The Phototherapy segment is forecasted to reach a value of 1.49 USD Billion by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
